Company intelligence / Profile preview

BioMarker Pharmaceuticals

Campbell, California, United States

Ownership: Private
Employees: ~10
Development stage: Other

Overview

BioMarker Pharmaceuticals has demonstrated the use of gene-expression-based screening to rapidly identify potential anti-aging compounds, showing that the effects of caloric restriction and certain drugs on gene expression can be manifested within weeks in animal models. The company reports preclinical evidence for metformin as a promising anti-aging agent and has evaluated proprietary herbal formulations for healthspan extension. There are no clinical-stage drug programs or late-stage clinical results available in the public domain.

Therapeutic areas: CardiovascularOtherImmunologyMetabolic Disorders
Modalities: Small moleculeHerbal formulationNutraceutical
Industry: Non-Drug Biotech

Partnerships

Life Extension (funding partner[3])

Beyond the preview

Go deeper on BioMarker Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioMarker Pharmaceuticals.

Explore the full profile